Follow-up of patients with inflammatory myopathies and a biobank

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a cohort of patients with inflammatory myopathies to better understand the disease's underlying mechanisms and identify potential treatments. It will involve collecting a wide range of clinical, radiological, and biological data, including muscle biopsies and blood samples, to establish a biobank. Patients will undergo regular follow-up visits to assess muscle strength, function, and other relevant health metrics. The goal is to delineate factors contributing to myositis and improve prognostication based on various clinical variables.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Suspicion of Myositis defined according to reference classifications: Dermatomyositis (DM), polymyositis (PM) defined as early as 1975 by Bohan and Peter, inclusion myositis (IM) according to the criteria of Griggs et al, 1995 and autoimmune necrotizing myopathy (ANM) by Hoogendijk et al, in 2004 and iatrogenic (e.g. drug-induced) myositis.
* No opposition from patients to the use of their data
* Signature of consents for the constitution of the biobank and the genetic analyses

Exclusion Criteria:

* Patients under AME
* Patients under legal protection

Where it's running

• Département de médecine interne et immunolgie clinique, Hôpital Pitié Salpêtrière
  Paris, France Recruiting
• Département de pharmacologie clinique, Hôpital Pitié Salpêtrière
  Paris, France Recruiting

Study contacts

• Study coordinator: Joe-Elie SALEM, MD PhD
• Email: joe-elie.salem@aphp.fr
• Phone: 142178531

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases

  This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.

  Recruiting Early Phase 1 Peking University Third Hospital · Beijing · NCT07301164

• Investigating the role of platelets in autoimmune diseases

  This study looks at how activated platelets interact with immune cells in people with autoimmune diseases like lupus and scleroderma to see how these interactions might affect their condition.

  Recruiting University Hospital, Strasbourg, France · Strasbourg, France · NCT06593041

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• Umbilical cord lining stem cell infusions for adults with dermatomyositis or polymyositis

  This trial will test whether three IV infusions of umbilical cord lining stem cells help adults with dermatomyositis or polymyositis reduce symptoms and steroid needs.

  Recruiting at 2 sites Phase 2/3 Restem, LLC. · Gainesville, Florida and 1 other locations · NCT07160205

• Evaluating FT819 for autoimmune diseases

  This study is testing a new treatment called FT819 to see if it can safely help people with moderate to severe autoimmune diseases feel better.

  Recruiting at 21 sites Phase 1 Fate Therapeutics · Beverly Hills, California and 20 other locations · NCT06308978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.